Financials

  • Market Capitalization 27.61 M
  • Employee 44
  • Founded N/A
  • CEO N/A
  • Website www.cel-sci.com
  • Headquarter Colorado, United States
  • FIGI BBG000H5G6L5
  • Industry Biotechnology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
-1.47
Price to sales ratio
-57.5

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
4470
GRDX
GridAI Technologies Corp. - Common Stock
3.96 USD-1.25%+17.16%+54.69%+55.29%28.24 M USD
4473
NXTC
NextCure, Inc. - Common Stock
6.09 USD+0.83%+2.87%+22.29%-53.51%27.88 M USD
4476
BYSI
BeyondSpring, Inc. - Ordinary Shares
0.67 USD+4.69%-4.29%-40.71%-60.82%27.55 M USD
4480
NNVC
NanoViricides, Inc. Common Stock
1.24 USD-3.88%-5.34%-20.00%+22.76%26.84 M USD

Frequently asked questions about Cel-Sci Corporation

What is the Cel-Sci Corporation stock price today?

The current price of Cel-Sci Corporation (CVM) is 1.57. Over the past 24 hours, the stock has changed by -3.09%. Follow the CVM chart for real-time price dynamics.

What is the stock ticker of Cel-Sci Corporation?

Cel-Sci Corporation trades under the ticker CVM. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Cel-Sci Corporation stock going up?

CVM has changed by +10.56% over the last week, +34.19% over the last month, and -69.51% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Cel-Sci Corporation?

Cel-Sci Corporation currently has a market capitalization of 27.61 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What was Cel-Sci Corporation revenue for the last quarter?

Cel-Sci Corporation reported quarterly revenue of -110.24 K. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Cel-Sci Corporation net income for the last quarter?

Cel-Sci Corporation reported net income of -5.67 M for the last quarter. The previous quarter showed -5.47 M, which means net income changed by -3.69%.

How many employees does Cel-Sci Corporation have?

As of the latest available data, Cel-Sci Corporation has 44 employees. Workforce size can provide additional context about the company's scale and operations.

What is Cel-Sci Corporation EBITDA?

Cel-Sci Corporation EBITDA is -5.66 M, and its EBITDA margin is 5 137.45%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Cel-Sci Corporation stock?

You can buy Cel-Sci Corporation (CVM) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Cel-Sci Corporation stock?

Investing in Cel-Sci Corporation requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the CVM chart and related analysis on metatrader.com as part of your research.

Cel-Sci Corporation Common Stock

Cel-Sci Corporation, is a biotechnology company that tests drugs for the treatment of cancer, autoimmune and infectious diseases through the research and development of immunotherapy products. Cel-Sci's main product is the drug Multikine, an immunotherapeutic agent designed to fight cancer by stimulating the body's immune system. Multikine is currently in Phase III of Clinical Trials with the Food and Drug Administration. Multikine has also been referred to as Leukocyte Interleukin Injection. Multikine was in Phase II testing of patients with head and neck cancer in the early 2000s, in which it demonstrated tumor-reducing ability. In January 2007, the US cleared the Phase 3 trial and Multikine was designated as an orphan drug by the FDA for neoadjuvant therapy of patients with squamous cell carcinoma of the head and neck. A total of 928 patients were enrolled in the head and neck cancer drug trial at that time. Subsequently, in June 2021, the company announced that the study missed its primary endpoint.

News